Archive · 7 Jan 2026
At-home blood tests detect Alzheimer's biomarkers accurately
Scientists have found a new way to test for Alzheimer's disease using a simple finger-prick blood test that can be done at home.
This test can detect important signs of Alzheimer's in the blood, similar to more complicated tests done in hospitals.
The study showed that this at-home test is quite accurate, around 86%, and can help more people, especially those in remote areas, get tested for Alzheimer's.
This could make it easier for doctors to find and treat people with Alzheimer's early, before they show symptoms.
The test also measures other important markers in the blood that are linked to brain changes.
While it's not ready for use in clinics yet, this new method could help in research and include more people in studies, especially those who don't have easy access to healthcare.
At-home finger-prick blood tests can accurately detect Alzheimer's biomarkers like p-tau217.
The study, published in Nature Medicine, involved 337 participants across seven European medical centres.
The tests showed 86% accuracy in identifying Alzheimer's-related changes compared to traditional methods.
Additional markers, GFAP and NfL, were also successfully measured with strong agreement to traditional tests.
This method could enable remote participation in Alzheimer's research and clinical trials, especially in underrepresented communities.
- Who
- Researchers from multiple European medical centres and Professor Nicholas Ashton, senior director of US-based Banner Health
- What
- Developed a method to detect Alzheimer's biomarkers using at-home blood tests
- When
- Study published in Nature Medicine
- Where
- Seven European medical centres
- Why
- To make Alzheimer's disease detection more accessible and remove geographic barriers
Proponents of at-home testing
Cautious stakeholders
Accessibility vs. Clinical Readiness
Proponents of at-home testing
Proponents highlight the potential of at-home testing to make Alzheimer's detection more accessible, especially in remote areas and underrepresented communities, and to facilitate remote participation in research and clinical trials.
Cautious stakeholders
Cautious stakeholders emphasize that while the method shows promise, it is not yet ready for clinical use and requires further validation before it can be widely adopted in healthcare settings.
- Study Publication
- Nature Medicine
- Sample Type
- Finger-prick blood samples
- Key Biomarker
- p-tau217
- Accuracy
- 86%
- Participants
- 337
- Locations
- Seven European medical centres
- Additional Markers
- GFAP and NfL
